November 21, 2024 /

Webinar: RGX-202 – AFFINITY DUCHENNE Pivotal Program and Functional Data

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

During this community webinar, REGENXBIO provides an update on its AFFINITY DUCHENNE trial of RGX-202, a next-generation microdystrophin gene therapy. REGENXBIO’s Dr. Naz Dastgir discusses the company’s pivotal trial plans and shares interim clinical data, including the first functional data for RGX-202.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo